Research & Development

In a significant breakthrough for neurodegenerative medicine, Swiss biotechnology firm AC Immune has announced highly encouraging interim results from a clinical trial of its experimental Parkinson's disease vaccine. The therapy, ACI-7104, represents a pioneering approach that aims not just to

A new pharmaceutical agent is now demonstrating the ability to help individuals shed nearly a third of their body weight, a result that blurs the line between medication and major surgical intervention. This development represents more than just another option in the fight against obesity; it

The perplexing and often heartbreaking phenomenon of cancer recurrence following initially successful treatment has long been a central challenge in oncology, driving a significant number of cancer-related fatalities worldwide. Patients and clinicians are frequently confronted with the reality that

Today, we have the privilege of speaking with Ivan Kairatov, a biopharma expert with extensive experience in oncology research and development. We'll be dissecting the groundbreaking results from the HER2CLIMB-05 trial, a study that introduces a significant potential shift in the first-line

An extensive analysis of a recent international study highlights a significant advancement in treating early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, which is the most common subtype affecting approximately 70% of all patients. The landmark lidERA clinical trial

In the persistent and complex war against cancer, one of the greatest hurdles has always been the enemy's cunning ability to evade destruction, but a newly unveiled biological process, termed triaptosis, offers a groundbreaking strategy to circumvent this resistance by inducing a novel form of